Related references
Note: Only part of the references are listed.ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma
T. Powles et al.
ANNALS OF ONCOLOGY (2021)
Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program
Laurence Albiges et al.
EUROPEAN JOURNAL OF CANCER (2021)
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study.
Laure Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
Sumanta K. Pal et al.
LANCET (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.
Chung-Han Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma
Guangxi Sun et al.
NATURE COMMUNICATIONS (2021)
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets
Anna Calio et al.
PATHOLOGY (2020)
Cabozantinib in non-clear cell metastatic renal cell carcinoma and sarcomatoid renal cell carcinoma: Real-world data from the CABOREAL study
A. Flechon et al.
ANNALS OF ONCOLOGY (2020)
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
Nieves Martinez Changa et al.
LANCET ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Toni K. Choueiri et al.
EUROPEAN JOURNAL OF CANCER (2018)
Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool
Paul W. Sperduto et al.
NEURO-ONCOLOGY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders
A. Boileve et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Recommendations for the Management of Rare Kidney Cancers
Rachel H. Giles et al.
EUROPEAN UROLOGY (2017)
Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas
Marion Classe et al.
HISTOPATHOLOGY (2017)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
Prognosis of brain metastasis (BM) in metastatic renal cell carcinoma (mRCC): Experience from Gustave Roussy (IGR)
Annalisa Guida et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
Laurence Albiges et al.
CLINICAL CANCER RESEARCH (2014)
International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia
Brett Delahunt et al.
EUROPEAN UROLOGY (2014)
Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma
Rana R. McKay et al.
EUROPEAN UROLOGY (2014)
Clinical heterogeneity of Xp11 transiocation renal cell carcinoma: impact of fusion subtype, age, and stage
Carla L. Ellis et al.
MODERN PATHOLOGY (2014)
Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers
Eric C. Kauffman et al.
NATURE REVIEWS UROLOGY (2014)
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors
Andrew J. Wagner et al.
CANCER (2012)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network
G. G. Malouf et al.
ANNALS OF ONCOLOGY (2010)
Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Adult Metastatic Xp11.2 Translocation Renal Cell Carcinoma
Toni K. Choueiri et al.
CANCER (2010)
Adult Xp11 Translocation Renal Cell Carcinoma Diagnosed by Cytogenetics and Immunohistochemistry
Yoshinobu Komai et al.
CLINICAL CANCER RESEARCH (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition
Masumi Tsuda et al.
CANCER RESEARCH (2007)
Share Paper
